Subsequent large trials with other SGLT2-Is, such as canagliflozin (CANVAS (Canagliflozin Cardiovascular Assessment Study) [33] and CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trials [34]) and dapagliflozin (DECLARE-TIMI 58 (Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes) trial [35]), confirmed these observations in a broader population of primary and secondary prevention patients [36,37]. This evidence concerns the gene SLC5A2 and kidney disorder.